There is mounting evidence of the druggability of human Cdc20 to interfere with APC/C functions in cancer cells, where the attention has been centred on the development of compounds that bind the Cdc20 D-box located in the C-terminal of the WD40 domain. The gene discussed is CDC20; the disease is cancer.